contact us
sort news by author
Andy Peel, Caitlin Wilkinson, Caoimhe McElduff, Charlotte Stockton, David Laws, Edward Jones, Emma Petela, GK Strategy, Harry Shackleton, Ian Perrin, Isabelle Hillson, Jack Sansum, James Page, Jamie Cater, Jennifer Berger, Joe Berkhout, Joe Cormack, Johnny Munro, Louise Allen, Luke Kennedy, Mark Fuller, Martin Summers, Megan Baxter, Ned Lamb, Olivia Rohll, Rebecca Lury, Robin Grainger, Sarah De Rosa, Tim Farazmand, Tim Swabey, Viya Nsumbu,
sort news by category
Insight, Strategy, Impact,
awards, B2G, Bills, Boris, Brexit, business, careers, climate change, commissioning, Communications, Crisis comms, culture, Digital, Due Diligence, Education, Energy, Energy and Environment, Environment, Equality, ESG, EU, europe, Financial Services, General News, GK culture, Government, government affairs, Health, health funding, Healthcare, housing, HS2, infrastructure, insight, internship, Investment, Investor, Investor Backed Businesses, Investor Services, investors, labour conference, Legislation, mental health, NHS, No deal, parliament, pharma, Planning, policy, Political Due Diligence, Politics, Pride Month, Private Equity, Public Affairs, Public Relations, Queen's Speech, regulation, sales, Select Committee, Social Care, Strategic Communications, sustainability, Technology, The Labour Party, Transport, uk, UK Politics, Waste, women, Workplace,
When government policy provides value creation opportunities
Across the spectrum of due diligence there is, understandably, a focus on risk identification and assessment. This is also true for political, policy and regulatory due diligence, with PE deal-teams interested in whether and how Brexit or a Corbyn government could pose risks to an asset’s business model or key markets. But private equity and their companies are increasingly interested in how political and regulatory changes can drive market opportunities. Our due diligence is moving away...
Political Due Diligence , Government , government affairs , policy , Politics , UK Politics
2 min readEurope and the supply of innovative medicines: why it matters
One of the standout features of the ‘no-deal’ Brexit debate has been the focus on the impact on supplies of medicines and medicinal products. This includes everything from chemical compounds and investigational medicinal products (IMPs) for clinical research through to short shelf-life medicines made on the continent. The debate has been a continuous battle between those outlining the possible impact on patients’ lives while struggling to quantify the extent of the impact. Some areas...
What we’ve learned from Labour conference
It’s safe to say this was a Labour party conference unlike any other, with more disruption and changes of schedule than a Southern rail service. Amidst the confusion and grumblings over the party’s Brexit position though, there was debate, innovative policies and a positivity that Labour will have a transformative manifesto capable of winning the next election. GK were on the ground at conference and our key takeaways from the South Coast are: The mood in the party is as...
Private Equity investment in Pharma – why is the UK bucking the global trend?
In recent years we’ve become used to claims that the impasse of Brexit is drying up investment in UK life sciences. The argument also goes that global investment by pharmaceuticals in R&D – predicted to grow to $181 billion by 2022 – will instead flow to other countries. There is evidence that can support this theory but if you scrape below the surface and look at investment by private equity into life sciences the picture looks quite different. The figures actually suggest that...
Decision time for HS2: another victim of the UK’s infrastructure failings
Ten years since it was first launched, with £7.4bn already spent and yet another review announced, the benefits of HS2 are being questioned once again. Whilst arguments in favour of HS2 have remained unchanged for a decade – reduced travel times will boost the national economy and drive regional growth – the economic, technological and societal context have changed almost unrecognisably since 2009. It is a depressingly...
Vote for GK at the British Private Equity Awards 2019!
GK Strategy is delighted to be nominated as Specialist Due Diligence Provider of the Year in the Unquote British Private Equity Awards 2019. The shortlist is drawn up by a panel of industry experts and then opeen to a public vote, so we would really appreciate your support in voting for GK here:
Political Due Diligence , Due Diligence , Private Equity , awards
2 min readThe lost parliament? Analysing the 2017-19 session
Depending on your politics, the Prime Minister’s decision to shut down parliament from the 9th September until the 14th October is either a coup d’etat to thwart opponents of a no-deal Brexit or a natural end to the most unusual and most unproductive parliamentary session in history. Long time coming What makes the 2017-19 session unusual is its length - typically, parliamentary sessions last for one year. This parliamentary session has now overtaken the 296...
Engaging with the Conservative Party’s new policy forums
Since barrelling into Number 10 and laying down the law with civil servants, fellow special advisers and junior ministers in his first week, Dominic Cummings has given the impression that he alone is running the government. His ‘one strike and you’re out’ policy for leaks has already been widely derided, with an immediate leak from a dazed Spad last week confirming that...